Oct 25, 2022
Ymmunobio at the "Gateway to the Global Biopharma Community"
Ymmunobio CEO Dr. Katrin Rupalla and Dr. Bernhard Singer traveled to Leipzeig, Germany, for the BIO-Europe Start-up Spotlight. She presented our findings on the anti-tumor efficacy in anti-PD-1 sensitive and anti-PD-1 resistant in vivo Hepa1-6 models. The anti-tumor activity is correlated with changes in the immune compartment of the tumor microenvironment.
The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live pitch competition gives a group of hand-selected startups the opportunity to pitch in front of the BIO-Europe audience. Selected companies will present a four-minute pitch and participate in a live feedback session with a jury of leading investors, pharma dealmakers, and biotech business key opinion leaders who will evaluate the pitches and select the winner onsite.
BIO-Europe covenes over 5,000 attendees, representing 60 countries and 2,200 companies. It is the industry's largest gathering of biopharma professionals in Europe.